[go: up one dir, main page]

HUP0003256A2 - Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents

Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP0003256A2
HUP0003256A2 HU0003256A HUP0003256A HUP0003256A2 HU P0003256 A2 HUP0003256 A2 HU P0003256A2 HU 0003256 A HU0003256 A HU 0003256A HU P0003256 A HUP0003256 A HU P0003256A HU P0003256 A2 HUP0003256 A2 HU P0003256A2
Authority
HU
Hungary
Prior art keywords
pentosan polysulfate
chronic progressive
treating chronic
medicament useful
progressive vascular
Prior art date
Application number
HU0003256A
Other languages
English (en)
Inventor
Gary E. Striker
Liliane J. Striker
Original Assignee
The United States of America, represented by The Secretary, Department of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25283204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0003256(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The United States of America, represented by The Secretary, Department of Health & Human Services filed Critical The United States of America, represented by The Secretary, Department of Health & Human Services
Publication of HUP0003256A2 publication Critical patent/HUP0003256A2/hu
Publication of HUP0003256A3 publication Critical patent/HUP0003256A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány pentozán-poliszulfát (PPS) vagy annak gyógyászatilagelfogadható sója alkalmazására vonatkozik a megbetegedettérrendszerben az erek lumenének szűkülését és rugalmasságánakcsökkenését okozó krónikus progresszív vaszkuláris hegesedéssel járóbetegségben (CPVSD) szenvedő emlősök kezelésére használható, abetegség kifejlődését leállító és a már kialakult heges sérülésekeltűnését vagy csökkenését kiváltó hatású gyógyászati készítményekelőállítására. Ó
HU0003256A 1997-04-16 1998-04-10 Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases HUP0003256A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/840,777 US20010005720A1 (en) 1995-06-07 1997-04-16 Method of treating chronic progressive vascular scarring diseases

Publications (2)

Publication Number Publication Date
HUP0003256A2 true HUP0003256A2 (hu) 2001-02-28
HUP0003256A3 HUP0003256A3 (en) 2001-12-28

Family

ID=25283204

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003256A HUP0003256A3 (en) 1997-04-16 1998-04-10 Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases

Country Status (17)

Country Link
US (1) US20010005720A1 (hu)
EP (1) EP0986392A4 (hu)
JP (1) JPH1149802A (hu)
KR (1) KR20010006511A (hu)
CN (1) CN1259871A (hu)
AR (1) AR008559A1 (hu)
AU (1) AU750182B2 (hu)
BR (1) BR9809396A (hu)
CA (1) CA2285950A1 (hu)
HU (1) HUP0003256A3 (hu)
IL (1) IL132389A0 (hu)
NO (1) NO995024L (hu)
NZ (1) NZ500527A (hu)
SK (1) SK142599A3 (hu)
TW (1) TW557213B (hu)
WO (1) WO1998046237A1 (hu)
ZA (1) ZA982246B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005292202A1 (en) * 2004-10-01 2006-04-13 Keryx Biopharmaceuticals, Inc. Methods using glycosaminoglycans for the treatment of kidney disease
WO2010103837A1 (ja) 2009-03-11 2010-09-16 ゼライス株式会社 アテローム性動脈硬化症の進行抑制薬・予防薬・血中コレステロール低下薬・機能性食品・特定保健用食品
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
MX2020002288A (es) 2016-08-31 2020-07-14 Oji Holdings Corp Metodo de produccion para xilooligosacarido acido y xilooligosacarido acido.
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
SG11201911318SA (en) 2017-05-31 2020-01-30 Oji Holdings Corp Moisturizing topical preparation
KR102678054B1 (ko) 2017-09-12 2024-06-24 오지 홀딩스 가부시키가이샤 폴리황산펜토산 및 폴리황산펜토산의 제조 방법
HUE062342T2 (hu) 2017-12-20 2023-10-28 Oji Holdings Corp Pentozán-poliszulfát, valamint pentozán-poliszulfátot tartalmazó gyógyszerek
WO2023070164A1 (en) * 2021-10-28 2023-05-04 Paradigm Biopharmaceuticals Ltd Treatment of heart failure with preserved ejection fraction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
AR008559A1 (es) 2000-01-19
SK142599A3 (en) 2001-12-03
AU7248298A (en) 1998-11-11
BR9809396A (pt) 2000-06-13
WO1998046237A1 (en) 1998-10-22
IL132389A0 (en) 2001-03-19
US20010005720A1 (en) 2001-06-28
CA2285950A1 (en) 1998-10-22
ZA982246B (en) 1998-09-17
EP0986392A1 (en) 2000-03-22
CN1259871A (zh) 2000-07-12
AU750182B2 (en) 2002-07-11
JPH1149802A (ja) 1999-02-23
NO995024D0 (no) 1999-10-15
KR20010006511A (ko) 2001-01-26
TW557213B (en) 2003-10-11
NO995024L (no) 1999-12-13
NZ500527A (en) 2001-10-26
HUP0003256A3 (en) 2001-12-28
EP0986392A4 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
HU9301978D0 (en) Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin
HUP9800467A2 (hu) Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
SE9902597D0 (sv) New use
DE69921348D1 (de) Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
CN112569222A (zh) 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
WO2020232120A2 (en) Methods for treating arthritis using spl-108 peptide
Dawe et al. Effects of a xanthine derivative, oxpentifylline, on certain psychological parameters of behaviour and performance
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
RU2135091C1 (ru) Способ лечения варикозных язв
SU1680189A1 (ru) Способ лечени аутоиммунного тиреоидита
Schaefer et al. Milestone-Multicentre lloprost European study on endangiitis: a controlled double-blind study to determine the efficacy of Iloprost, a stable PGI2-analogue, in patients with thromboangiitis obliterans (Buerger's disease)
Petrov et al. Thrombolytic action of fibrinogen-modified urokinase
RU2146884C1 (ru) Способ лечения диффузного токсического зоба
周立群 How to Promote the Therapeutic Effect of Auriculotherapy in the Treatment of Vascular Hypertension?
Kaplan et al. Peristomal pyoderma gangrenosum